‎PureHealth Q2 2026 earnings forecasts

ProcIntel Risk Index (PRI) PRI indicates how much procurement risk attention a canonical event warrants, based on its potential impact, corroboration, linked-entity criticality, geographic or regulatory exposure, and confidence in the available evidence. — historical only (this event is rejected, so PRI is not shown as current customer-facing intelligence, but its calculation history below is preserved). — 9 · Minimal Freshness: Ageing DATA QUALITY WARNING

PRI: 9 — MINIMAL Base risk 21/100 × Low confidence multiplier (0.45). Highest contributor: Significance 41/100, normalised to this factor's 40-point cap (+16 of 40). Limiting factor: Linked-entity criticality 0/100, normalised to this factor's 30-point cap -- DATA QUALITY WARNING: no eligible entities (30 points below its maximum). DATA QUALITY WARNING: no eligible entities.

Confidence multiplier Confidence limits the final PRI when evidence is uncertain. A severe but weakly supported claim cannot reach the highest PRI bands.: 0.45 (Low) · Calculated just now (vv1).

Full contribution breakdown

Procurement Impact: 16 / 40 — Significance 41/100, normalised to this factor's 40-point cap
Corroboration: 5 / 15 — A single event -- not yet corroborated by a separate clustered event (neutral baseline, not a penalty)
Entity Criticality: 0 / 30 — Linked-entity criticality 0/100, normalised to this factor's 30-point cap -- DATA QUALITY WARNING: no eligible entities
Geographic Regulatory: 0 / 15 — 0 distinct content-linked geography/geographies

Event type

Supply shortage

UUID

e8b83b39-524d-44f0-8504-0ab9224ba747

Editorial review status

Rejected (ProcIntel's own review of this record)

Event lifecycle

Breaking (the real-world state of the situation — a separate concept from review status above)

Significance

3 · Material

This type of disruption typically has a moderate procurement impact.
No specific geography identified yet.
No specific companies or organisations linked yet.
Assessed time horizon: Short-term.

Confidence

2 · Low (distinct from each article link's own extraction confidence below)

Reported only by secondary sources so far — no primary/official confirmation yet.
Reported by a single source so far — not yet independently corroborated.
Some key facts (e.g. exact date) are still missing or unconfirmed.
Evidence was last updated within the last month.

Impact direction

Negative (provisional default — not yet reviewed)

Occurred at

Not yet established (no explicit date was tightly bound to the matched event text)

Record type

REAL

Source Facts

‎<img src="https://argaamplus.s3.amazonaws.com/05e5b960-d2a7-412d-9a23-09cc9678dd29.png" >Pure Health logo <hr> Argaam, in this report, provides an overview of PureHealth expected results for Q2 2026 along with trends in quarterly revenue and earnings, in addition to key operating and profitability indicators. Quarterly Revenue – AED mln <table border="0" cellpadding="0"> <thead> <tr> <th > Item </th> <th > 2Q 2025 </th> <th > 3Q 2025 </th> <th > 4Q 2025 </th> <th > 1Q 2026 </th> <th > 2Q 2026 (Consensus) </th> </tr> </thead> <tbody> <tr> <td > Revenue </td> <td > 6,993.0 </td> <td > 6,527.2 </td> <td > 7,210.8 </td> <td > 7,262.3 </td> <td > 7,352.0 </td> </tr> <tr> <td > Change (%) </td> <td > +9.5% </td> <td > +1.2% </td> <td > +4.6% </td> <td > +10.4% </td> <td > +5.1% </td> </tr> </tbody> </table> Quarterly Earnings– AED mln <table border="0" cellpadding="0"> <thead> <tr> <th > Item </th> <th > 2Q 2025 </th> <th > 3Q 2025 </th> <th > 4Q 2025 </th> <th > 1Q 2026 </th> <th > 2Q 2026 (Consensus) </th> </tr> </thead> <tbody> <tr> <td > Net income </td> <td > 522.3 </td> <td > 520.8 </td> <td > 455.2 </td> <td > 386.6 </td> <td > 394.8 </td> </tr> <tr> <td > Exceptional item </td> <td > 0.0 </td> <td > 0.0 </td> <td > 535.6* </td> <td > 0.0 </td> <td > 0.0 </td> </tr> <tr> <td > Net income before exceptional and non-recurring items </td> <td > 522.3 </td> <td > 520.8 </td> <td > (80.5) </td> <td > 386.6 </td> <td > 394.8 </td> </tr> <tr> <td > EPS excluding non-recurring items (AED/share) </td> <td > 0.05 </td> <td > 0.05 </td> <td > (0.01) </td> <td > 0.03 </td> <td > 0.04 </td> </tr> </tbody> </table> * Operating expense grant income of AED 437.4 million, capital expenditure grant income of AED 43.5 million, reversal of management incentives amounting to AED 42.5 million, and a gain of AED 12.2 million from the disposal of property and equipment. Key events in Q2 2026 Shareholders approved a cash dividend of AED 0.0541 per share for 2025. The company inaugurated a campus for the University of Nicosia in Athens, Greece, in the presence of senior officials. The campus will offer medical education integrating artificial intelligence with clinical training. The initiative aims to strengthen UAE-Greece cooperation, help address Europe's healthcare workforce shortage by linking academic education with scientific research and provide exchange and practical training programs. The company announced that its insurance arm, Daman, received an A1 Insurance Financial Strength Rating from Moody's Ratings with a stable outlook, the highest rating among insurers in the UAE and the GCC. The rating reflects the company's financial strength and the successful transformation of Daman into a comprehensive and sustainable insurance platform. Average forecasts The company is forecast to report a net profit of AED 394.8 million, 24% lower year-on-year (YoY), according to the average estimates of two research houses. Average estimates – AED mln <table border="0" cellpadding="0"> <thead> <tr> <th > Research House </th> <th > Forecast (AED mln) </th> </tr> </thead> <tbody> <tr> <td > FAB Securities </td> <td > 467.0 </td> </tr> <tr> <td > Bank of America </td> <td > 322.6 </td> </tr> <tr> <td > Consensus </td> <td > 394.8 </td> </tr> <tr> <td > Net profit before exceptional and non-recurring items (2Q 2025) </td> <td > 522.3 </td> </tr> <tr> <td > Difference (%) </td> <td > (24%) </td> </tr> </tbody> </table> Stock performance <table border="0" cellpadding="0"> <thead> <tr> <th > Metric </th> <th > Company </th> <th > Market </th> </tr> </thead> <tbody> <tr> <td > Change YTD </td> <td > (12.94%) </td> <td > (1.53%) </td> </tr> <tr> <td > Change over the last 12 months </td> <td > (26.97%) </td> <td > (4.86%) </td> </tr> <tr> <td > Previous close </td> <td > 2.22 </td> <td > 9,839.56 </td> </tr> <tr> <td > Recurring P/E </td> <td > 18.28x </td> <td > 22.39x </td> </tr> <tr> <td > Trailing 12-month EPS excluding non-recurring items (AED/share) </td> <td > 0.121 </td> <td > -- </td> </tr> </tbody> </table> <div ></div>

Linked Signals

Published	Headline	Source	Matched text	Extraction confidence	Method
2026-07-30 12:43:00	‎PureHealth Q2 2026 earnings forecasts	Argaam - UAE News	workforce shortage	95.0	high precision phrase

Linked Entities

No entities linked yet

Spend Categories

No spend categories linked yet

Spend categories are linked by a reviewer, not assigned automatically.

Review History

Date	Action	Previous	New	Reviewer	Note
2026-07-31 08:58:50	Created	—	Supply shortage: '\u200ePureHealth Q2 2026 earnings forecasts' (lifecycle=Breaking)	Deterministic v1 extractor	—
2026-07-31 08:58:50	Article Linked	—	source_item #442	—	—
2026-07-31 08:58:50	Significance Changed	None	3	—	—
2026-07-31 08:58:50	Confidence Changed	None	2	—	—
2026-07-31 09:02:27	Review Status Changed	pending	rejected	Stage 6.6 cleanup	Stale: matched only via the broad "\w+ shortages?" pattern tried during Stage 6.6, which was reverted after finding false positives. Does not match under the current, narrower phrase list.